This performance reflects our team's focus to capitalize on growth opportunities across the many end markets we serve, with particular success this quarter in packaging and consumer, our two largest end markets.” 2 Dr. Three Months Ended June 30, 2024 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS $ EPS Net income from continuing operations attributable to Avient shareholders $ 33.6 $ 0.36 $ 22.1 $ 0.24 Special items, after-tax (Attachment 3) 21.8 0.24 19.6 0.21 Amortization expense, after-tax 14.8 0.16 16.2 0.18 Adjusted net income / EPS $ 70.2 $ 0.76 $ 57.9 $ 0.63 Six Months Ended June 30, 2024 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS $ EPS Net income from continuing operations attributable to Avient shareholders $ 83.0 $ 0.90 $ 42.9 $ 0.47 Special items, after-tax (Attachment 3) 27.3 0.30 41.9 0.46 Amortization expense, after-tax 29.7 0.32 31.3 0.34 Adjusted net income / EPS $ 140.0 $ 1.52 $ 116.1 $ 1.27 8 Attachment 2 Avient Corporation Condensed Consolidated Statements of Income (Unaudited) (In millions, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales $ 849.7 $ 824.4 $ 1,678.7 $ 1,670.1 Cost of sales 592.1 583.7 1,142.9 1,181.8 Gross margin 257.6 240.7 535.8 488.3 Selling and administrative expense 185.1 178.4 369.3 368.9 Operating income 72.5 62.3 166.5 119.4 Interest expense, net (26.6) (29.4) (53.2) (58.2) Other (expense) income, net (0.9) (0.2) (1.8) 0.5 Income from continuing operations before income taxes 45.0 32.7 111.5 61.7 Income tax expense (11.2) (10.4) (28.0) (18.1) Net income from continuing operations 33.8 22.3 83.5 43.6 Loss from discontinued operations, net of income taxes — — — (0.9) Net income $ 33.8 $ 22.3 $ 83.5 $ 42.7 Net income attributable to noncontrolling interests (0.2) (0.2) (0.5) (0.7) Net income attributable to Avient common shareholders $ 33.6 $ 22.1 $ 83.0 $ 42.0 Earnings (loss) per share attributable to Avient common shareholders - Basic: Continuing operations $ 0.37 $ 0.24 $ 0.91 $ 0.47 Discontinued operations — — — (0.01) Total $ 0.37 $ 0.24 $ 0.91 $ 0.46 Earnings (loss) per share attributable to Avient common shareholders - Diluted: Continuing operations $ 0.36 $ 0.24 $ 0.90 $ 0.47 Discontinued operations — — — (0.01) Total $ 0.36 $ 0.24 $ 0.90 $ 0.46 Cash dividends declared per share of common stock $ 0.2575 $ 0.2475 $ 0.5150 $ 0.4950 Weighted-average shares used to compute earnings per common share: Basic 91.3 91.1 91.3 91.1 Diluted 92.2 91.9 92.0 91.9 9 Attachment 3 Avient Corporation Summary of Special Items (Unaudited) (In millions, except per share data) Special items (1) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Cost of sales: Restructuring costs, including accelerated depreciation $ 0.2 $ (1.2) $ 3.8 $ (7.8) Environmental remediation costs (21.8) (13.0) (25.8) (14.4) Impact on cost of sales (21.6) (14.2) (22.0) (22.2) Selling and administrative expense: Restructuring and employee separation costs (2.8) (0.5) (3.5) (11.9) Legal and other (2.3) (6.4) (5.8) (10.6) Acquisition related costs (0.5) (0.7) (2.1) (4.2) Impact on selling and administrative expense (5.6) (7.6) (11.4) (26.7) Impact on operating income (27.2) (21.8) (33.4) (48.9) Interest expense, net - financing costs (1.0) — (1.0) — Other income (loss) 0.1 0.1 0.1 (0.1) Impact on income from continuing operations before income taxes (28.1) (21.7) (34.3) (49.0) Income tax benefit on above special items 7.0 5.5 8.4 12.4 Tax adjustments(2) (0.7) (3.4) (1.4) (5.3) Impact of special items on net income from continuing operations $ (21.8) $ (19.6) $ (27.3) $ (41.9) Diluted earnings per common share impact $ (0.24) $ (0.21) $ (0.30) $ (0.46) Weighted average shares used to compute adjusted earnings per share: Diluted 92.2 91.9 92.0 91.9 (1) Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt extinguishment costs; costs incurred directly in relation to acquisitions or divestitures; employee separation costs resulting from personnel reduction programs, plant realignment costs, executive separation agreements; asset impairments; settlement gains or losses and mark-to- market adjustments associated with gains and losses on pension and other post-retirement benefit plans; environmental remediation costs, fines, penalties and related insurance recoveries related to facilities no longer owned or closed in prior years; gains and losses on the divestiture of operating businesses, gains and losses on facility or property sales or disposals; results of litigation, fines or penalties, where such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non- recurring items; and the effect of changes in accounting principles or other such laws or provisions affecting reported results 2) Tax adjustments include the net tax impact from non-recurring income tax items, adjustments to uncertain tax position reserves and the establishment, reversal or changes to valuation allowances. 10 Attachment 4 Avient Corporation Condensed Consolidated Balance Sheets (In millions) (Unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 489.4 $ 545.8 Accounts receivable, net 486.6 399.9 Inventories, net 365.9 347.0 Other current assets 117.2 114.9 Total current assets 1,459.1 1,407.6 Property, net 1,019.9 1,028.9 Goodwill 1,685.1 1,719.3 Intangible assets, net 1,515.7 1,590.8 Other non-current assets 228.0 221.9 Total assets $ 5,907.8 $ 5,968.5 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term and current portion of long-term debt $ 657.7 $ 9.5 Accounts payable 435.2 432.3 Accrued expenses and other current liabilities 405.3 331.8 Total current liabilities 1,498.2 773.6 Non-current liabilities: Long-term debt 1,420.8 2,070.5 Pension and other post-retirement benefits 63.3 67.2 Deferred income taxes 276.3 281.6 Other non-current liabilities 315.0 437.6 Total non-current liabilities 2,075.4 2,856.9 SHAREHOLDERS' EQUITY Avient shareholders’ equity 2,317.5 2,319.2 Noncontrolling interest 16.7 18.8 Total equity 2,334.2 2,338.0 Total liabilities and equity $ 5,907.8 $ 5,968.5 11 Attachment 5 Avient Corporation Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions) Six Months Ended June 30, 2024 2023 Operating Activities Net income $ 83.5 $ 42.7 Adjustments to reconcile net income to net cash provided (used) by operating activities: Depreciation and amortization 88.4 96.2 Accelerated depreciation 0.8 1.9 Share-based compensation expense 9.0 6.5 Changes in assets and liabilities: Increase in accounts receivable (97.0) (66.6) (Increase) decrease in inventories (27.3) 14.0 Increase (decrease) in accounts payable 11.9 (26.2) Taxes paid on gain on sale of business — (103.0) Accrued expenses and other assets and liabilities, net (6.2) 9.8 Net cash provided (used) by operating activities 63.1 (24.7) Investing activities Capital expenditures (55.8) (45.9) Net proceeds from divestiture — 7.3 Proceeds from plant closures 3.4 — Other investing activities (2.1) — Net cash used by investing activities (54.5) (38.6) Financing activities Cash dividends paid (47.0) (45.0) Repayment of long-term debt (4.5) (1.0) Other financing activities (3.3) (2.3) Net cash used by financing activities (54.8) (48.3) Effect of exchange rate changes on cash (10.2) (0.8) Decrease in cash and cash equivalents (56.4) (112.4) Cash and cash equivalents at beginning of year 545.8 641.1 Cash and cash equivalents at end of period $ 489.4 $ 528.7 12 Attachment 6 Avient Corporation Business Segment Operations (Unaudited) (In millions) Operating income and earnings before interest, taxes, depreciation and amortization (EBITDA) at the segment level does not include: special items as defined in Attachment 3; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; share-based compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker.

Ha Ön bármikor olyan, trösztellenes szempontból érzékeny tevékenységekbe kíván kezdeni, amelyek hatással bírhatnak akár az USA-n belül, akár azon kívül, akkor előzetesen egyeztessen az Avient jogi osztályával. 2 „Ajánlattétel összehangolása” az, amikor az összejátszó versenytársak előzetesen megegyeznek abban, hogy ki fogja benyújtani a nyertes ajánlatot egy szerződésre egy versenytárgyalási folyamat során. Ügyletkötés elutasítása – Megállapodás egy versenytárssal arra vonatkozóan, hogy bojkottáljanak egy harmadik vállalatot, vagy ne kössenek ügyletet azzal. 2. Kerülje a felesleges kapcsolatot a versenytársakkal. 2.

Закон Шермана: • запрещает соглашения, которые необоснованно ограничивают торговлю (включая фиксирование цен, ограничение объема производства, распределение покупателей или территорий между конкурентами, коллективные бойкоты и некоторые ограничения распределения и лицензирования); • объявляет незаконными монополии, а также попытки и сговоры с целью монополизации (даже безуспешные). 2. Всякий раз, когда ожидается участие в деятельности, несущей риски в антимонопольной сфере, на территории США или за ее пределами, необходимо заранее консультироваться с юридическим отделом 2 «Сговор на торгах» — когда вступившие в сговор конкуренты заранее договариваются о том, кто подаст выигрышную заявку на заключение контракта при проведении конкурсных торгов. Избегайте ненужного взаимодействия с конкурентами. 2.

Declara ilícitos los monopolios y los intentos y conspiraciones para monopolizar (incluso si no tienen éxito). 2. Negativas a negociar: acuerdo con un competidor para boicotear o no negociar con una tercera empresa. 2. Evite el contacto innecesario con la competencia. 2.

De Sherman-wet: • Verbiedt overeenkomsten die handel op onredelijke wijze beperken (waaronder prijsafspraken, productiebeperking, toewijzing van klanten of gebieden tussen concurrenten, groepsboycot en sommige distributie- en licentiebeperkingen) • Verkondigt onwettige monopolies en pogingen en complotten om te monopoliseren (zelfs als ze niet slagen) 2. Weigering om te handelen: een overeenkomst met een concurrent om een derde bedrijf te boycotten of er niet mee te handelen. 2. Vermijd onnodig contact met concurrenten. 2.

Um Acordo de venda casada é uma prática que envolve o condicionamento da venda de um produto à concordância do cliente de também comprar um produto “casado” diferente. 2 “Fraude a licitação” ocorre quando concorrentes conspiram e combinam previamente quem enviará a proposta vencedora de um contrato, durante a participação em um processo de licitação de concorrência. Recusas de negociação: acordo com um concorrente para boicotar ou não negociar com uma terceira empresa. 2. Evite contatos desnecessários com concorrentes. 2.

To check this certificate validity ptease call: +31 (0) 88 450 5500 Page I of 2 R [{$l'll. fluA I sYs. 248 Avient protective Materiats Urmonderbaan 22, 6167 RD Geteen, The Nethertands 5750 Martin Luther King Jr.

APPLICATIONS: Power cables, Ethernet category cables, industrial cables, solar installation cables, coaxial cables, fiber optics, hybrid cables SYNCURE™ Cross-Linked Polyethylene for Power Cable Insulation • Resistant to heat, oil, creep and abrasion • Fast extrusion speeds • UL 44 & UL 4703 flame performance • UL/CSA bulletins MAXXAM™ FR W&C Flame Retardant Polypropylene for Category Cable Insulation and Cross-Webs • Alternative to FEP • Low dielectric • Thin wall extrusion capabilities • UL 94 & plenum yellow card, V-2, V-0 & 5VA fire performance ratings FIRECON™ Flame Retardant Chlorinated Polyethylene for Industrial Cable Jackets • Resistance to harsh environments • Low temperature properties • UV resistance • UL 44 flame performance ECCOH™ LSFOH Low Smoke and Fume, Non-Halogen for Insulation and Jackets • Low smoke and toxicity • Improved fire safety • Resistance to chemicals • UL44 and CPR flame performance ADDITIONAL SOLUTIONS MAXXAM™ SY Foamed Polypropylene for Coaxial Cable Insulation SYNPRENE™ Flame Retardant Thermoplastic Elastomers POLYMIX™ Customer Proprietary Formulations For more information, please visit avient.com or call +1.844.4AVIENT (+1.844.428.4368).

EXTRUDER Screw 3/4" to 6" Polyethylene type—Single flight, no mixing section, 1.5–2:1 compression ratio Tooling Semi-Pressure type: 30°–40° angle Die On size with 1/8" or less land L/D 24:1 recommended Screen Pack No screen pack (Optional depending on pressure) Cooling Trough 120–150°F (50–65°C) recommended Feeder Gravimetric type preferred—3 compartment for cross-linked Dryer Desiccant type, 4 hours at 160°F (70°C) For ECCOH™ compound only; never put Dry Silane in Dryers PROCESSING Temperature ECCOH 5000 Series ECCOH 6000 Series Wire Preheat 180–250°F (80–120°C) 180–250°F (80–120°C) Feed Zones 200°F (93°C) 275°F (135°C) Transition 275°F (135°C) 325°F (163°C) Metering 300°F (150°C) 375°F (190°C) Head/Die 330°F (165°C) 420°F (215°C) Target Melt 330–340°F (165–170°C) 420–440°F (215–225°C) Flame at Die Tip Yes—as needed Line Speed Shear sensitive: Observe Melt Temperature, Motor Amperage, and Pressure Purge Compound HDPE Copyright © 2020, Avient Corporation.

Nikrant Page 67 United States 36% Europe 36% Canada 2% Asia 20% Latin America 2011 Revenue: $0.6 Billion2011 Revenue: $0.6 Billion SolutionsSolutions At a Glance Appliance 6% Building & Construction 3% Wire & Cable 14% Electrical & Electronics 14%Consumer 21% Packaging 5% Industrial 8% Misc. 3% HealthCare 5% Transportation 21% America 6% 2011 Revenue by Industry Segment2011 Revenue by Industry Segment 1.1% 1.3% 3.4% 5.1% 9.6% 8.0% 12-16% 2006 2007 2008 2009 2010 2011 2015 Operating Income % of Sales Target Expanding ProfitsExpanding Profits Page 68 Value Proposition • GSEM is a global leader providing complete specialty solutions encompassing innovative technologies and services to enable customer success Transformation Highlights • Dramatic turnaround of the Engineered Materials business through mix improvement and specialty focus Value Proposition and Transformation Highlights improvement and specialty focus • GLS acquisition successfully integrated, having more than doubled earnings in 3 years • PolyOne culture and strategy now engrained worldwide • Expansion into healthcare with dedicated resources > $15B Addressable Market Page 69 • Polymer design, formulation and service expertise • Broad, global technology base and regional centers of excellence • Ten innovation centers around the world Key Differentiators • Ten innovation centers around the world • Specialty brand leadership with PolyOne, GLS, NEU and ECCOH • Ability to leverage global key account team Page 70 From Volume Commodity-driven product portfolio To Value Specialty technology and solutions EM North America Transformation Volume Sales Gross Margin $ Mix Transformation – Executing the Strategy 2006 2011 2006 2011 2006 2011 Page 71 $12 $29 Operating Income ($ in millions) • Provided access to new customers in specialized, high-growth markets such as healthcare and consumer • Strategic partner to many of the world’s best-known companies GLS Integration Success 16.9% 8.2% 2007 2011 2007 2011 Working Capital % of Sales • Complementary global footprint provided additional cross-selling opportunities • Opportunity to expand margins and drive working capital improvement while remaining customer-focused Page 72 $1.3 $27.6 2006 2011 Healthcare Revenue • Investment in dedicated healthcare team to drive penetration and growth • Leverage product portfolio globally & win specialty business Areas of Focus $10.5 $117.9 2006 2011 Consumer Revenue 2006 2011globally & win specialty business in targeted markets • Aggressively commercialize specialty innovation platforms • Utilize our innovation centers to influence OEM design (Revenue in $ millions) Page 73 • Carbon Nanotube Formulations � Applications: Semiconductor equipment, hard drives � Customer benefits: Scrap cost reduction and clean conductivity • Thermally Conductive Solutions Applications: Sockets and bulb holders for LED lighting Key Innovations � Applications: Sockets and bulb holders for LED lighting � Customer benefits: Cost reduction, energy saving, and design flexibility • FDA-Regulated TPEs � Applications: Food packaging seals, intravenous delivery systems, medical stoppers, prefilled syringes � Customer benefits: Clean and safe elastomers for highly regulated applications Page 74 Critical Imperatives and 2015 Goal Critical Imperatives • Commercialize critical new technology platforms • Manage the mix as we continue to drive the transformation • Global translation of commercial successes 2015 Goal • 12 - 16% return on sales Page 75 Page 76